Several recent studies have indicated the involvement of calcium-dependent mechanisms, in particular the abundant calcium-activated kinase, calcium/calmodulin-dependent kinase II (CaMKII), in behaviors associated with nicotine dependence in mice. Behavioral and biochemical studies have shown that CaMKII is involved in acute and chronic nicotine behaviors and nicotine withdrawal; however, evidence of a role for CaMKII in nicotine reward is lacking. Thus, the goal of the current study was to examine the role of CaMKII in nicotine reward. Using pharmacological and genetic tools, we tested nicotine conditioned place preference (CPP) in C57Bl/6 mice after administration of CaMKII antagonists and in α-CaMKII wild-type (+ / + ) and heterozygote (± ) mice. CaMKII antagonists blocked expression of nicotine CPP, and the preference score was significantly reduced in α-CaMKII ± mice compared with their + / + counterparts. Further, we assessed CaMKII activity in the ventral tegmental area (VTA), nucleus accumbens (NAc), prefrontal cortex, and hippocampus after nicotine CPP and found significant increases in CaMKII activity in the mouse VTA and NAc that were blocked by CaMKII antagonists. The findings from this study show that CaMKII mediates nicotine reward and suggest that increases in CaMKII activity in the VTA and NAc are relevant to nicotine reward behaviors. Behavioural Pharmacology 27:50-56
Introduction
Nicotinic acetylcholine receptors (nAChRs) are pentameric, calcium-permeable, cholinergic receptors that form ligand-gated ion channels and are the primary targets through which nicotine exerts its effects. The binding of nicotine to its receptors leads to an influx of and subsequent rise in intracellular calcium. This, in turn, leads to the activation of several downstream pathways and second messengers, including calcium/ calmodulin-dependent protein kinase II (CaMKII), a highly abundant serine threonine-specific kinase that is essential for long-term potentiation and neurotransmitter release (Schulman and Hanson, 1993; Lisman et al., 2002) , and calcium/calmodulin-dependent protein kinase IV (CaMKIV), a less abundant kinase involved in the regulation of activity-triggered gene expression (Deisseroth et al., 1998) . Several lines of recent evidence have emerged, suggesting an important role for these kinases in mediating nicotine-associated behaviors.
L-type calcium channels and CaMKII are involved in nicotine-induced antinociception in mice (Damaj, 2000 (Damaj, , 2005 (Damaj, , 2007 . In addition, L-type calcium channel, CaMKII, and CaMKIV mechanisms are involved in physical and affective nicotine withdrawal behaviors (Biala and Weglinska, 2005; Jackson et al., 2012) . Molecular studies have shown that β2-containing nAChRs mediate acute nicotine-induced increases in CaMKII activity in the ventral tegmental area (VTA), nucleus accumbens (NAc), and amygdala . Further, phosphorylated CaMKII levels are increased in the NAc following chronic exposure to nicotine in mice (Jackson and Damaj, 2013) . In contrast, significant reductions in phosphorylated CaMKII levels in the NAc are observed after cessation of nicotine treatment in nicotine-dependent mice (Jackson and Damaj, 2013) . Human genetic studies have also indicated that variants of the CaMKIV gene are associated with a protective effect in nicotine dependence (Jackson et al., 2012) . Although there is an emerging consensus that calcium-dependent mechanisms facilitate aspects of nicotine addiction-related behaviors, information on the role of these mechanisms in nicotine reward is limited. Recent studies have shown that nicotine reward, as measured by the conditioned place preference (CPP) test, is attenuated in CaMKIV knockout (− / − ) mice, and the CaMKIV level is increased in the NAc after nicotine CPP in mice (Jackson et al., 2012) ; however, the role of the more abundant kinase, CaMKII, in nicotine reward is unclear.
In the current study, we sought to complement previous behavioral findings from our laboratory indicating a role for CaMKII in acute and chronic nicotine behaviors (Damaj, 2000 (Damaj, , 2005 (Damaj, , 2007 Jackson and Damaj, 2013) and nicotine withdrawal ) by examining the involvement of brain CaMKII activity and function in nicotine reward using the CPP test. To this end, biochemical and behavioral approaches were used, as well as genetically modified mice. We first investigated the involvement of CaMKII in nicotine reward using the CPP test following intracerebroventricular administration of CaMKII membranepermeable selective inhibitors, KN-62 and KN-93, and the inactive analog, KN-92. α-CaMKII − / − mice have deficits in spatial learning, decreased anxiety-related responses, and increased susceptibility to seizures (Silva et al., 1992; Butler et al., 1995) . Although memory retention is impaired in α-CaMKII heterozygote ( ) mice at longer retention delays (10-50 days), learning and recent memory are normal in these mice at 1-3 days after training (Frankland et al., 2001) . Thus, to complement our pharmacological approach and avoid the potential factors in α-CaMKII − / − mice that may confound our results, we tested nicotine preference in α-CaMKII mice and their wild-type (+ / + ) counterparts. Food reward studies were also conducted as a control to assess the potential for learning deficits in α-CaMKII mice in the CPP test. Finally, we measured changes in CaMKII activity in several brain regions in nicotine-treated mice after the CPP test.
Methods

Subjects
Adult male C57BL/6J mice, male α-CaMKII mice (Camk2atm1Sva-targeted mutation), and male α-CaMKII + / + littermates were purchased from Jackson Laboratories (Bar Harbor, Maine, USA). Animals were housed in groups of six in a 21°C, humidity-controlled, Association for Assessment and Accreditation of Laboratory Animal Care-approved animal care facility with food and water freely available. The rooms were on a 12 h light/dark cycle (lights on at 07:00 h). Mice were 8-10 weeks old and weighed ∼ 25-30 g at the start of the experiment. All experiments were performed during the light cycle and were approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University.
Intracerebroventricular surgery
Mice undergoing intracerebroventricular surgeries for the administration of CaMKII antagonists were anesthetized with an intraperitoneal injection of 45 mg/kg sodium pentobarbital. An incision was made on the scalp of the mouse midway between the eyes and ears to expose cranial sutures. The skin that was cut resulted in a flap, which was put back into place at the end of the surgery to keep the site free from debris. Using the stereotaxic apparatus, an injection was made through the dura mater with the following coordinates: − 0.6 mm AP and + 1.3 mm ML with respect to the bregma, and − 2.1 mm DV from the surface of the skull. After the surgery, the animals were returned to clean home cages and were allowed to recover for 24 h.
Nicotine conditioned place preference
A nicotine CPP test (n = 6-8 per group) was conducted on independent groups of C57Bl/6 mice and α-CaMKII and + / + mice using an unbiased design, as previously described by Kota et al. (2007) . In brief, mice were handled for 3 days before initiation of CPP testing. The CPP apparatus was a three-chambered box with a white compartment, a black compartment, and a center gray compartment. The black and white compartments also had different floor textures to help the mice further differentiate between the two environments. On Day 1, the mice were placed in the center gray compartment for a 5-min habituation period, followed by a 15-min test period to determine baseline responses. A prepreference score was recorded and used to counterbalance and randomly pair each mouse with either the black or the white compartment so that an even number of mice received the drug in either environment. Over the next 3 days, the mice were conditioned twice a day, once in the morning (07:00-09:00 h) and once in the afternoon (14:00-16:00 h), for 20 min, with the saline group receiving saline on both sides of the boxes and the drug groups receiving nicotine (0.5 mg/kg, subcutaneously) on one side of the box and saline on the opposite side. On the evening of Day 4, after removal from the CPP chambers, C57Bl/6 mice underwent intracerebroventricular surgery for administration of the CaMKII inhibitors.
On the CPP test day (Day 5), the CaMKII inhibitor KN-62 (0.01 and 0.05 μg), a structurally different CaMKII inhibitor KN-93 (0.05 μg), and its inactive analog KN-92 (0.05 μg) were injected intracerebroventricularly directly into the skulls of C57Bl/6 mice using a Hamilton syringe. Sterile saline-soaked cotton swabs were used to lightly nudge the flap of skin to expose the injection site while gently restraining the mouse by holding the nape of the neck. A volume of 5 μl of the CaMKII inhibitor, the inactive analog, or the vehicle were administered, with the syringe being held in place for 30 s to allow time for drug diffusion into the lateral ventricle. Following the injection period, the animals were returned to their home cages and allowed 5 min to recover from the light restraint required for injection before being placed into the CPP chamber. α-CaMKII and + / + mice did not undergo surgery at any time during the experiment or receive any drug treatment on the test day. The test day procedure was the same as the Day 1 procedure. Data were expressed as time spent on the drug-paired side after conditioning minus time spent on the drug-paired side before conditioning. A positive number indicated a preference for the drug-paired side, whereas a negative number indicated an aversion to the drug-paired side. A number at or near zero indicated no preference for either side.
Food conditioned place preference
For food-induced CPP, palatable food (Kraft Classic Philadelphia Cheesecake; Kraft, Deerfield, Illinois, USA) was used to induce place preference in mice. Briefly, the mice underwent preconditioning on Day 1 and were divided into groups of equal bias, as described above. The mice were immediately introduced to palatable food for the next 4-6 h. The conditioning days followed the same experimental design as described above except that the mice received cheesecake or a standard chow pellet control instead of drug or saline; one extra day of conditioning was required to obtain significant place preference scores (days 2-5), and each conditioning session lasted 40 min.
CaMKII activity assay
Separate groups of C57Bl/6 mice receiving vehicle, nicotine, or KN-62 (0.05 μg, intracerebroventricular; n = 5 per group) were killed by cervical dislocation immediately after removal from the CPP chambers on the test day. Brains were removed and the NAc, VTA, prefrontal cortex (PFC), and hippocampus (Hipp) and were dissected and homogenized in calcium-free Tris buffer containing 1 mmol/l phenylmethylsulfonyl fluoride. The samples were centrifuged to separate the membrane and the cytosol-containing kinase. Cytosol homogenates were normalized for protein concentration. CaMKII activity was measured using a CaMKII-specific assay kit (Millipore, Billerica, Massachusetts, USA). Standard phosphorylation reaction solutions contained 70 μg protein, 10 mmol/l MgCl 2 , 0.1 mmol/l EGTA, 1 μCi [ 32 P] ATP, 10 mmol/l PIPES pH 7.4, 5 μmol/l CaCl 2 , and 5 μg calmodulin. Standard reactions were performed in a shaking water bath at 30°C. CaMKII activity was determined using the following formula: 
Statistical analysis
For all data, statistical analyses were carried out using StatView (SAS Institute Inc., Cary, North Carolina, USA). Data from CPP studies using CaMKII inhibitors or food and from the CaMKII activity assays were analyzed using one-way analysis of variance (ANOVA), with treatment as the between-subject factor. Data from CPP studies using α-CaMKII and + / + mice were analyzed using two-way ANOVA, with treatment and genotype as between-subject factors. Significant results and interactions from the two-way ANOVA were further assessed using a Newman-Keuls post-hoc test. P-values less than 0.05 were considered significant.
Results
CaMKII inhibitors block expression of nicotine conditioned place preference in mice
Male C57Bl/6 mice were conditioned with saline or nicotine (0.5 mg/kg, subcutaneous) and treated with the structurally different CaMKII inhibitors, KN-62 (0.01 or 0.05 μg, intracerebroventricular), KN-93 (0.05 μg, intracerebroventricular), or the inactive KN-93 analog, KN-92 (0.05 μg, intracerebroventricular), on the test day. Results are shown in Fig. 1 . Nicotine produced a robust CPP in C57Bl/6 mice [F (9,63) = 10.99, P < 0.001]. Expression of nicotine CPP was significantly blocked by the highest dose of KN-62 (0.05 μg, intracerebroventricular) and by KN-93 (0.05 μg, intracerebroventricular). KN-92 did not significantly alter the expression of nicotine CPP. The doses of KN-62 and KN-93 used in this assessment did not produce a significant behavioral response in salinetreated mice.
Nicotine conditioned place preference is reduced in α-CaMKII ± mice
Male α-CaMKII + / + and mice were conditioned with saline or nicotine (0.25 or 0.5 mg/kg, subcutaneous). Results are shown in Fig. 2 . There were significant main effects of treatment [F (2,36) = 17.59, P < 0.001] and genotype [F (1,36) = 4.36, P < 0.05], and a significant treatment × genotype interaction [F (2,36) = 3.44, P < 0.05]. Nicotine induced a significant CPP in α-CaMKII + / + mice at 0.25 and 0.5 mg/kg and in α-CaMKII mice at 0.5 mg/kg; however, CPP was significantly reduced at 0.5 mg/kg in α-CaMKII mice compared with their + / + counterparts. Baseline CPP scores did not significantly differ between genotypes or treatments.
Food conditioned preference in α-CaMKII ± and + / + mice
We assessed palatable food-induced CPP in α-CaMKII + / + and mice as a control to assess the potential for learning deficits (Fig. 3) . After 4 days of conditioning, both α-CaMKII + / + and mice displayed similar place preference scores for the context associated with palatable food [F (3,21) = 18.52, P < 0.001].
Nicotine CPP-induced increases in CaMKII activity in the VTA and NAc are blocked by To complement our behavioral approach, CaMKII activity was analyzed in the VTA, NAc, PFC, and Hipp of C57Bl/6 mice after nicotine CPP using a CaMKIIspecific assay kit. The results are shown in Fig. 4 . Nicotine CPP is reduced in α-CaMKIV mice. Nicotine induced a significant CPP in α-CaMKII + / + mice at 0.25 and 0.5 mg/kg, and in α-CaMKII mice at 0.5 mg/kg; however, CPP was reduced in α-CaMKII mice at 0.5 mg/kg compared with their + / + counterparts. Each point represents the mean SEM of six to eight mice per group. *Significant main effects of treatment. P < 0.05 versus α-CaMKII nicotine (0.5 mg/ kg) counterparts. + , significant interaction; CaMKII, calcium/ calmodulin-dependent kinase II; CPP, conditioned place preference; NIC; nicotine; SAL, saline; Veh, vehicle. 
Palatable food
Food CPP is maintained in α-CaMKIV mice. α-CaMKII and α-CaMKII + / + mice showed similar place preference scores for the context associated with the appetitive food stimulus. Results are expressed as mean preference scores SEM. *P < 0.05 versus standard chow controls. CaMK, calcium/calmodulin-dependent kinase; CPP, conditioned place preference.
CaMKII activity was significantly increased in the VTA [ Fig. 4a; F (3,16) = 9.77, P < 0.001] and NAc [ Fig. 4b ; F (3,16) = 44.32, P < 0.001] membrane portions after nicotine CPP, but not in the PFC (Fig. 4c) or Hipp (Fig. 4d ). KN-62 significantly decreased nicotine-induced increases in CaMKII activity the VTA and NAc after the CPP test, but it did not significantly alter CaMKII activity in the NAc or VTA of saline-conditioned mice.
Discussion
Recent evidence indicates an important role for calciumdependent mechanisms in nicotine-mediated behaviors. Thus, the goal of the current study was to complement previous studies supporting a role for such mechanisms in nicotine responses by determining the role of the most abundant calcium-mediated protein in the brain, CaMKII, in nicotine reward. Pharmacological and genetic studies using CaMKII antagonists and genetically modified α-CaMKII mice have shown that blockade or reduction of CaMKII reduces nicotine reward, as measured in the CPP test. Further, biochemical studies have indicated that increases in CaMKII activity in the VTA and NAc are blocked by CaMKII antagonists. Our findings support a role for CaMKII in mediating nicotine reward and show that increases in CaMKII activity in the VTA and NAc are relevant in nicotine reward mechanisms. A limitation to the study is the use of α-CaMKII mice, which could lead to some difficulties in interpretation as the mice still possess 50% of the enzyme activity. However, the use of pharmacological agents, that is, CaMKII inhibitors, complements the genetic studies and strengthens the validity of these findings.
The decreased nicotine CPP observed after administration of CaMKII antagonists and in α-CaMKII mice coincides with the increase in CaMKII activity in the VTA and NAc in the CPP test. These two brain regions are part of the mesolimbic dopaminergic pathway and play a central role in nicotine reward behaviors. NAChRs in the VTA mediate nicotine-induced release of the neurotransmitter dopamine in the NAc (Sziraki et al., 2002) . CaMKII is essential for neurotransmitter release (Schulman and Hanson, 1993) ; thus, it may mediate changes in dopamine function relevant to nicotine reward. It is observed that, although CaMKII inhibitors were injected intracerebroventricularly into the lateral ventricle, likely penetrating the entire brain, nicotine CPP-induced increases in CaMKII activity were region specific. The blockade of nicotine CPP-induced increases in CaMKII activity in the VTA and NAc further indicates that CaMKII-mediated mechanisms, specifically in these two brain regions, contribute to alterations in nicotine reward.
CaMKII is necessary for long-term potentiation, a cellular mechanism that underlies learning and memory (Lisman et al., 2002) . On the basis of this, another explanation for our results is that pharmacological inhibition of CaMKII may disrupt memory recall on the test day, as CaMKII has been shown to be involved in this process (Wang et al., 2003) . However, our complementary genetic studies using α-CaMKII mice show a reduction in CPP on the test day similar to that in the pharmacological studies. In addition, food reward studies reveal a similar expression of food CPP in α-CaMKII + / + and mice, suggesting that disruption of learning and memory processes may not be a major contributing factor in the current study. Importantly, the finding of similar place preference profiles to palatable food in α-CaMKII + / + mice and their littermates suggests that partial blockade of α-CaMKII does not result in a general decrease in reward, specifically pertaining to the natural incentive for food.
Although were reported previously to be selective inhibitors of CaMKII (Tokumitsu et al., 1990; Sumi et al., 1991) , they were more recently shown to also block CaMKIV (Enslen et al., 1994) . As previously shown in our laboratory, CaMKIV also mediates nicotine reward mechanisms, as nicotine CPP is attenuated in CaMKIV − / − mice, and the CaMKIV protein level is increased in the NAc after nicotine CPP (Jackson et al., 2012) ; therefore, it is possible that some of the observed behavioral effects may also be mediated by CaMKIV, as we did not observe total blockade of nicotine CPP in α-CaMKII mice. However, α-CaMKII mice possess 50% of the active CaMKII enzyme, and this level may be sufficient to maintain development of some nicotine CPP. Results may also suggest that α-CaMKII mice are less sensitive to the rewarding effects of nicotine and may acquire nicotine CPP at higher doses. It is also possible that CaMKII inhibition decreases the effectiveness of nicotine as a stimulus in general. Another explanation, although less likely, is that genetic reduction of α-CaMKII may have potentiated the aversive effects of nicotine, which could explain the decrease in nicotine CPP responses. Future studies using higher doses of nicotine would address these possibilities. Nonetheless, we suggest that our pharmacological and genetic behavioral results support the involvement of CaMKII in mechanisms of nicotine reward.
In summary, the pharmacological, genetic, and biochemical findings from this study indicate that CaMKII activity mediates nicotine reward and emphasize the relevance of CaMKII activity in the VTA and NAc in mediating these behaviors. This work further supports the importance of calcium-dependent mechanisms, in particular CaMK, in behaviors that contribute to nicotine dependence.
